Curative Biotechnology Inc Total Liabilities
Curative Biotechnology Inc total liabilities. Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has total liabilities worth $8.37 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Curative Biotechnology Inc (CUBT) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Curative Biotechnology Inc (2013–2025)
Total liabilities of Curative Biotechnology Inc from 2013 to 2025. This chart illustrates how Curative Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data.
Curative Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Curative Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RECYCLICO BATTERY METALS
F:ID4
|
Germany | €4.43 Million |
|
Damodar Industries Limited
NSE:DAMODARIND
|
India | Rs-1.48 Billion |
|
Solis Minerals Ltd
V:SLMN
|
Canada | CA$505.04K |
|
Blackrock Smaller Companies Trust PLC
LSE:BRSC
|
UK | GBX77.48 Million |
|
Mexican Gold Corp
V:MEX
|
Canada | CA$134.27K |
|
Atlas Cycles (Haryana) Limited
NSE:ATLASCYCLE
|
India | Rs966.27 Million |
|
Slam Exploration Ltd.
V:SXL
|
Canada | CA$391.43K |
|
FG Financial Group
NASDAQ:FGF
|
USA | $23.52 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Curative Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CUBT asset base.
Liquidity & Leverage Metrics
Curative Biotechnology Inc Total Liabilities Ratios Explained
Curative Biotechnology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curative Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curative Biotechnology Inc (2013–2025)
The table below shows the annual total liabilities of Curative Biotechnology Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.20 Million | +15.83% |
| 2024-12-31 | $7.08 Million | +23.15% |
| 2023-12-31 | $5.75 Million | -74.60% |
| 2022-12-31 | $22.62 Million | +20.48% |
| 2021-12-31 | $18.77 Million | +176.26% |
| 2020-12-31 | $6.80 Million | +1611.33% |
| 2019-12-31 | $397.10K | -45.93% |
| 2018-12-31 | $734.36K | +2.23% |
| 2017-12-31 | $718.33K | +2.28% |
| 2016-12-31 | $702.29K | +2.20% |
| 2015-12-31 | $687.16K | -28.50% |
| 2014-12-31 | $960.99K | +3.04% |
| 2013-12-31 | $932.66K | -- |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more